DE102009047243A1 - Monospezifische Polypeptidreagenzien - Google Patents

Monospezifische Polypeptidreagenzien Download PDF

Info

Publication number
DE102009047243A1
DE102009047243A1 DE102009047243A DE102009047243A DE102009047243A1 DE 102009047243 A1 DE102009047243 A1 DE 102009047243A1 DE 102009047243 A DE102009047243 A DE 102009047243A DE 102009047243 A DE102009047243 A DE 102009047243A DE 102009047243 A1 DE102009047243 A1 DE 102009047243A1
Authority
DE
Germany
Prior art keywords
seq
fusion polypeptide
igg
domain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102009047243A
Other languages
German (de)
English (en)
Inventor
Robert Poppe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
POPPE, ROBERT, DR., DE
Original Assignee
Orgentec Diagnostika GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orgentec Diagnostika GmbH filed Critical Orgentec Diagnostika GmbH
Priority to DE102009047243A priority Critical patent/DE102009047243A1/de
Priority to AU2010323144A priority patent/AU2010323144B2/en
Priority to PCT/EP2010/068134 priority patent/WO2011064257A2/de
Priority to JP2012540419A priority patent/JP2013511966A/ja
Priority to US13/512,206 priority patent/US9163079B2/en
Priority to EP10798744.8A priority patent/EP2504359B1/de
Priority to DK10798744.8T priority patent/DK2504359T3/da
Priority to CA2782016A priority patent/CA2782016C/en
Publication of DE102009047243A1 publication Critical patent/DE102009047243A1/de
Priority to US14/848,636 priority patent/US9815891B2/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE102009047243A 2009-11-27 2009-11-27 Monospezifische Polypeptidreagenzien Withdrawn DE102009047243A1 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE102009047243A DE102009047243A1 (de) 2009-11-27 2009-11-27 Monospezifische Polypeptidreagenzien
AU2010323144A AU2010323144B2 (en) 2009-11-27 2010-11-24 Monospecific polypeptide reagents
PCT/EP2010/068134 WO2011064257A2 (de) 2009-11-27 2010-11-24 Monospezifische polypeptidreagenzien
JP2012540419A JP2013511966A (ja) 2009-11-27 2010-11-24 単一特異性ポリペプチド試薬
US13/512,206 US9163079B2 (en) 2009-11-27 2010-11-24 Monospecific polypeptide reagents
EP10798744.8A EP2504359B1 (de) 2009-11-27 2010-11-24 Monospezifische polypeptidreagenzien
DK10798744.8T DK2504359T3 (da) 2009-11-27 2010-11-24 Monospecifikke polypeptidreagenser
CA2782016A CA2782016C (en) 2009-11-27 2010-11-24 Monospecific polypeptide reagents
US14/848,636 US9815891B2 (en) 2009-11-27 2015-09-09 Monospecific polypeptide reagents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102009047243A DE102009047243A1 (de) 2009-11-27 2009-11-27 Monospezifische Polypeptidreagenzien

Publications (1)

Publication Number Publication Date
DE102009047243A1 true DE102009047243A1 (de) 2011-06-01

Family

ID=43589669

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102009047243A Withdrawn DE102009047243A1 (de) 2009-11-27 2009-11-27 Monospezifische Polypeptidreagenzien

Country Status (8)

Country Link
US (2) US9163079B2 (https=)
EP (1) EP2504359B1 (https=)
JP (1) JP2013511966A (https=)
AU (1) AU2010323144B2 (https=)
CA (1) CA2782016C (https=)
DE (1) DE102009047243A1 (https=)
DK (1) DK2504359T3 (https=)
WO (1) WO2011064257A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2413087T3 (es) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
US20170023576A1 (en) * 2014-04-04 2017-01-26 Oncomed Pharmaceuticals, Inc. Notch3 antibodies and uses thereof
WO2018037092A1 (en) * 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
CA3042236A1 (en) 2016-10-28 2018-05-03 Washington University Anti-apoe antibodies
EP3908664A4 (en) * 2019-01-07 2023-01-25 Thomas Jefferson University MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USES
AU2020301529B2 (en) 2019-06-24 2026-03-26 Universität Stuttgart TNFR2 agonists with improved stability

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
EP1018019B1 (en) 1996-01-23 2003-08-20 Abbott Laboratories Reagents for use as calibrators and controls
WO2006117782A2 (en) * 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002462A1 (en) 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Immunoglobulin superfamily domains and fragments with increased solubility
US6151296A (en) 1997-06-19 2000-11-21 Qualcomm Incorporated Bit interleaving for orthogonal frequency division multiplexing in the transmission of digital signals
AU5597500A (en) * 1999-06-07 2000-12-28 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
DE10001372A1 (de) 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
HUE029021T2 (en) * 2005-06-21 2017-02-28 Xoma (Us) Llc IL-1beta-binding antibodies and fragments thereof
ATE452913T1 (de) * 2005-08-26 2010-01-15 Pls Design Gmbh Bivalente igy antikörperkonstrukte für diagnostische und therapeutische anwendungen
EP1962961B1 (en) * 2005-11-29 2013-01-09 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
US8273030B2 (en) 2005-12-01 2012-09-25 Atcor Medical Pty Ltd Method of estimating pulse wave velocity
CA2646329C (en) * 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
EP2144930A1 (en) * 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
MX2009011342A (es) * 2007-04-20 2009-11-05 Invista Tech Sarl Fileta compacta de desenrollamiento continuo por encima con control de tension.
JP5511654B2 (ja) * 2007-05-31 2014-06-04 ゲンマブ エー／エス 分子操作により得られた組換え非グリコシル化一価半抗体
EP2116555A1 (en) * 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
EP1018019B1 (en) 1996-01-23 2003-08-20 Abbott Laboratories Reagents for use as calibrators and controls
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
WO2006117782A2 (en) * 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
Barthelemy et al. (2007) J. Biol. Chem. 283: 3639-54
Berman et al. (2003), Nature Structural Biology 10: 980
Boehm et al. (1999) J. Mol. Biol. 286: 1421-1447
DÜBEL,Stefan,u.a.:Rekombinante Antikörper.Biol. Unserer Zeit,34. Jahrgang 2004,Nr.6,Wiley-VCH Verlag GmbH,S.717-722 Abstr. Fig.1
DÜBEL,Stefan,u.a.:Rekombinante Antikörper.Biol. Unserer Zeit,34. Jahrgang 2004,Nr.6,Wiley-VCH Verlag GmbH,S.717-722 bstr. Fig.1$ *
Hollinger et al. (1993), PNAS 90: 6444-48
Hu et al. (1996), Cancer Res 56: 3055-61
Hu. et al. (1996), Cancer Research 56: 3055-61
Ichikawa et al. (1999), Arthritis and Rheumatism 42: 2461
Nieba et al. (1997), Protein Eng 10: 435-44
Perkins et al. (1991). J. Mol. Biol. 221: 1345-1366
Read et al. (2007), Appl. Environ. Microbiol. 73: 5088-96
TRINH,Ryan,et.al.:Optimization of codon pair use within the (GGGGS)3 linker sequence results in enhanced protein expression.Molecular Immonulogy 40,2004,S.372-379 Abb.4
TRINH,Ryan,et.al.:Optimization of codon pair use within the (GGGGS)3 linker sequence results in enhanced protein expression.Molecular Immonulogy 40,2004,S.372-379 bb.4$ *

Also Published As

Publication number Publication date
US9815891B2 (en) 2017-11-14
CA2782016A1 (en) 2011-06-03
US9163079B2 (en) 2015-10-20
CA2782016C (en) 2020-01-07
EP2504359B1 (de) 2016-03-23
AU2010323144B2 (en) 2013-11-07
JP2013511966A (ja) 2013-04-11
DK2504359T3 (da) 2016-07-25
AU2010323144A1 (en) 2012-07-12
US20160046703A1 (en) 2016-02-18
WO2011064257A2 (de) 2011-06-03
US20120276099A1 (en) 2012-11-01
WO2011064257A3 (de) 2011-08-11
EP2504359A2 (de) 2012-10-03

Similar Documents

Publication Publication Date Title
EP2504359B1 (de) Monospezifische polypeptidreagenzien
AU627183B2 (en) Method for producing recombinant dna proteins
DE69232604T2 (de) Antikörperkonstrukte
US5132405A (en) Biosynthetic antibody binding sites
US5091513A (en) Biosynthetic antibody binding sites
US6207804B1 (en) Genetically engineered antibody analogues and fusion proteins thereof
CN103429619A (zh) 双特异性和单特异性、不对称抗体和其制备方法
JP2005537009A (ja) 免疫系分子をヒト化する方法
TW202108613A (zh) 用於多聚化蛋白質及其分離的變異區域
US12000839B2 (en) Methods for characterizing disulfide bonds
CN115380210A (zh) 含多特异性抗原结合分子的组合物中的杂质分子的分析方法
CN116964084A (zh) 双特异性抗体
US20260009804A1 (en) Antibodies that bind to natively folded myocilin
DE202018006693U1 (de) Target-Detektion mit einem monovalenten Antikörper
CA3189938A1 (en) Antibody specific for mucin-1 and methods of use thereof
KR20190075071A (ko) 프래그먼트 항체 및 당해 프래그먼트 항체를 이용하는 단백질의 결정화 방법
JP6199054B2 (ja) 抗イヌＩｇＥモノクローナル抗体並びに抗イヌＩｇＥモノクローナル抗体の重鎖可変領域及び軽鎖可変領域
KR20240007767A (ko) CLDN18.2에 대한 단클론 항체 및 이의 Fc 조작된 형태
WO2026025029A1 (en) Method for selectively controlling the generation of degradants from a biological product exposed to a stress condition
EP3201328A1 (de) Fusionsprotein und aufreinigungsverfahren
CN120718146A (zh) 抗人TNF-β的单克隆抗体及其应用

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
R081 Change of applicant/patentee

Owner name: POPPE, ROBERT, DR., DE

Free format text: FORMER OWNER: ORGENTEC DIAGNOSTIKA GMBH, 55129 MAINZ, DE

R082 Change of representative

Representative=s name: WEICKMANN & WEICKMANN PATENTANWAELTE - RECHTSA, DE

Representative=s name: WEICKMANN & WEICKMANN PATENT- UND RECHTSANWAEL, DE

R005 Application deemed withdrawn due to failure to request examination